Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)

Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression. AstraZeneca PLC (ADR) (NYSE:AZN) now hopes that the use of the PARP inhibitor will be widened.

The trial revealed that women who are suffering from ovarian cancer and who have a BRCA gene that is defective are able to live approximately 19.1 months without the disease getting worse when they are taking Lynparza.

Patients who were on placebo were, by contrast, only able to live for 5.5 months without the disease worsening. Data also showed that when a central, blinded review was used to measure the progression of the disease, the number of months that a woman suffering from ovarian cancer was able to live without the disease getting worse was 30.2 months.

biotech, shares, market, amgen, percent, technical, economy, pharmaceutical, rate, quote, producer, drag, business, bio, capitalization, tech, biotechnology, sector, gain,,

g0d4ather/Shutterstock.com

Adverse Effects

Some of the more adverse effects that were experienced by the participants who took Lynparza include neutropenia and anemia. Anemia was observed in 19.5% of the cases while neutropenia was observed in 5% of the cases. Side effects caused around 11% of the participants to drop out of the trial.

Lynparza was one of the pioneering PARP inhibitors to get to the market after it received approval from the U.S. Food and Drug Administration three years ago. The approval, however, limited it to fourth-line use and the newest trial is meant to assist it in moving to being designated for second-line use. PARP inhibitors such as Lynparza work by blocking enzymes that are involved in the repair of damaged DNA and this helps to destroy cancer cells.

Follow Astrazeneca Plc (NYSE:AZN)
Trade (NYSE:AZN) Now!

TESARO Inc (NASDAQ:TSRO) Lagging Behind

Other pharmaceutical firms that possess PARP inhibitors include TESARO Inc (NASDAQ:TSRO) and Clovis Oncology Inc (NASDAQ:CLVS). Immediately after the announcement was made concerning the efficacy of Lynparza, the stock of Clovis Oncology Inc (NASDAQ:CLVS) went up while that of Tesaro took a beating. To treat ovarian cancer, Clovis Oncology Inc (NASDAQ:CLVS) has Rubraca which has already received approval from the U.S. Food and Drug Administration for use as a second-line therapy. Niraparib, which TESARO Inc (NASDAQ:TSRO) is developing, is currently in the third phase of a trial.

Follow Tesaro Inc. (NASDAQ:TSRO)
Trade (NASDAQ:TSRO) Now!

On Wednesday, shares of AstraZeneca PLC (ADR) (NYSE:AZN) fell slightly to close the day at $30.20.

Follow Clovis Oncology Inc. (NASDAQ:CLVS)
Trade (NASDAQ:CLVS) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.